William Parsons, MD
Dermatology · San Antonio, TXNPI 1811905417
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $7,180 of the $8,907 with a category attached, or 80.6%. AbbVie accounts for 87.8% of it on its own, with 19 other manufacturers making up the rest. Reporting peaked in 2024 at $5,310 and has fallen 96.9% since, to $167 in 2025.
Across 94 payments — averaging $94.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$8K
- Galderma Laboratories, L.p.$260
- Strata Skin Sciences, Inc.$106
- Regeneron Healthcare Solutions, Inc.$92
- Revance Therapeutics, Inc.$68
- UCB, Inc.$66
- plus $499 from 14 others
What the payments were for
- Speaking & faculty fees$7,18081%
- Food & beverage$1,72819%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 46 | $7,816 |
| Galderma Laboratories, L.p. | 5 | $260 |
| Strata Skin Sciences, Inc. | 7 | $106 |
| Regeneron Healthcare Solutions, Inc. | 6 | $92 |
| Revance Therapeutics, Inc. | 3 | $68 |
| UCB, Inc. | 2 | $66 |
| Lilly USA, LLC | 3 | $60 |
| Incyte Corporation | 2 | $60 |
| LEO Pharma Inc. | 3 | $54 |
| Sanofi | 2 | $41 |
| Sun Pharmaceutical Industries Inc. | 2 | $40 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 3 | $39 |
| Novartis | 2 | $38 |
| Amgen | 2 | $30 |
| Merz North America, Inc. | 1 | $28 |
| Sientra, Inc. | 1 | $27 |
| Integra Lifesciences Corporation | 1 | $24 |
| Biofrontera Inc. | 1 | $24 |
| Pfizer | 1 | $17 |
| Dermavant Sciences, Inc. | 1 | $17 |
How this compares
$8,907 in reported general payments places this provider in the 65th percentile of 1,098 dermatology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Clobetasol Propionate | 32 | $1,461 |
| Doxycycline Hyclate | 38 | $1,325 |
| Triamcinolone Acetonide | 48 | $379 |
| Desonide | 11 | $317 |
| Hydrocortisone | 24 | $184 |
| Mupirocin | 11 | $115 |
| Acyclovir | 15 | $84 |
Paid to pharmacies, not to this prescriber.
Other dermatology in San Antonio
- William CragunSan Antonio$2.2M
- Emily BeckerSan Antonio$1.2M
- Lindsey FinkleaSan Antonio$435K
- John BrowningSan Antonio$351K
- Vivian BucaySan Antonio$241K
- Annabelle GarciaSan Antonio$215K
- Edward LainAustin$2.5M
- Alpesh DesaiHouston$1.6M
- Craig TellerBellaire$1.3M
- Jennifer CatherDallas$1.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.